An interventional study of trapeziometacarpal arthroplasty and Trapeziectomy in Thumb Osteoarthritis, sponsored by Sahlgrenska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Sahlgrenska University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Osteoarthritis with a site in Sweden — 12 open to participants now, 25 under way, none of them phase 3. Osteoarthritis · Sweden.
Among the 78 studies in Osteoarthritis with a site in Sweden, this one is the 40th largest by planned enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2026, is one of 41 with no phase, reaches primary completion later than 15 of the 24 other live ones, and was the 77th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →12 of the 78 studies in Osteoarthritis with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18–75
Vastra Gotaland Region · Sites in Sweden
Ages 30+
Uppsala University · Sites in Sweden
Ages 18–100
Karolinska Institutet · Sites in Sweden
University Hospital, Basel, Switzerland · Sites in Sweden, Austria, Croatia and 5 more countries
Ages 18–70
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 5
First in 1997; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 98 across the 57 interventional studies, 500 across the 21 observational. Of the 42 that completed or were terminated, 12 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 78 have an industry lead sponsor. The 10 most frequent:
Sahlgrenska University Hospital is the lead sponsor of 264 studies on the registry; 69 are open to participants now.
Sahlgrenska University Hospital has 4 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04210687Karolinska InstitutetTrapeziectomy vs. Trapeziometacarpal Limited Excision for Thumb Base Osteoarthritis | 2026-12-01 |
| NCT05584410Vastra Gotaland RegionDigitalization of Osteoarthritis Care | 2026-12-31 |
| NCT07383740Vastra Gotaland RegionTest-Retest Reliability of a Submaximal Exercise Test in Patients With Hip and Knee Osteoarthritis | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies in Osteoarthritis with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Thumb carpometacarpal osteoarthritis is common and may cause severe pain and functional limitation. Trapeziectomy is widely used, whereas prosthetic arthroplasty may offer faster early recovery. However, detailed information on early postoperative and long-term radiological outcomes remains limited.
This is a single-centre, blinded randomised controlled trial at Sahlgrenska University Hospital, Gothenburg, Sweden. Adults aged 18-69 years with symptomatic thumb carpometacarpal osteoarthritis (Eaton grade 2-3) refractory to at least 3 months of non-operative treatment will be randomised 1:1 to trapeziometacarpal prosthetic arthroplasty or trapeziectomy. The primary outcome is day-by-day pain (registration on a numeric rating scale NRS, 0-10). Secondary outcomes include day-by-day analgesic consumption for 90 days, orthosis use after cast removal, patient-reported function (HQ-8, QuickDASH, and Nelson score) at 30, 45, 60, 75 and 90 days, assessor-measured range of motion and strength at 45 and 90 days, and long-term clinical follow-up at 6 months and 1, 2, 5 and 10 years. Cone beam computed tomography will be obtained in the arthroplasty group at 1 week postoperatively as reference and at 6 months and 1, 2, 5 and 10 years to assess implant position, migration and loosening. The target sample size is 64 participants (32 per group), providing 95% power to detect a 1-point between-group difference on the pain scale. Analyses will follow the intention-to-treat principle.
Aim and objectives The primary aim is to compare early postoperative pain trajectories after CMC-1 arthroplasty versus trapeziectomy for symptomatic thumb carpometacarpal osteoarthritis, using day-by-day patient-reported pain measurements during the first 90 postoperative days.
Secondary aims are to compare:
(i) Daily analgesic consumption during the first 90 postoperative days (ii) Orthosis use after cast removal (iii) Patient-reported hand/upper limb function using HQ-8, QuickDASH and Nelson score (iv) Blinded clinical measures of thumb range of motion, grip strength and pinch strength (v) Long-term clinical outcomes up to 10 years. Additionally, in the arthroplasty group, a long-term aim is to evaluate migration and radiological signs of implant loosening using cone beam computed tomography (CBCT). Similarly, in the trapeziectomy group, CBCT will be used to monitor and quantify metacarpal 1 proximal migration.
This protocol has been prepared in accordance with SPIRIT 2025 guidance [18], and includes a PRO EDI participant characteristics (Table 1).
Trial design This is a single-centre, assessor-blinded randomised controlled trial (RCT) with 1:1 allocation to prosthetic CMC-1 arthroplasty or trapeziectomy.
Study setting The study will be conducted at the Hand Surgery Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden. All operations will be performed by surgeons experienced in both techniques at least level 3 according to Giddins-Tang classification [19] and have at minimum overcome the previously described learning curve thresholds [20,21].
Eligibility criteria
Inclusion criteria:
Exclusion criteria:
Participant identification, recruitment and consent Potential participants will be identified among patients referred for surgical evaluation of symptomatic thumb carpometacarpal osteoarthritis at the study site. Eligible patients will receive verbal and written information about the study. Written informed consent will be obtained before any study-specific data collection.
At baseline, participants will complete the HQ-8, QuickDASH and Nelson score questionnaires. Baseline demographic characteristics will be recorded in line with the PRO
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Implantation of the Touch® CMC-1 prosthesis
Procedure: trapeziometacarpal arthroplasty
Surgical excision of the trapezium
Procedure: trapeziometacarpal arthroplasty · Procedure: Trapeziectomy
Participants allocated to arthroplasty will undergo implantation of the Touch® CMC-1 prosthesis according to routine practice at the study site. Surgery will be performed by experienced hand surgeons. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free.
Participants allocated to trapeziectomy will undergo surgical excision of the trapezium without tendon interposition according to routine practice at the study site. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free
Pain level
Patient-reported pain at the thumb base, measured on a 0-10 numeric rating scale (0 = no pain, 10 = worst imaginable pain).
Time frame: daily for three months
Analgesics used
Daily registration of analgesic consumption
Time frame: daily for three months
Use of Orthosis
• Orthosis use and perceived importance recorded weekly after cast removal
Time frame: Daily for three months
Patient-reported thumb symptoms
measured with Nelson score (a disease specific questionnaire)
Time frame: at 30, 45, 60, 75 and 90 postoperative days
Patient-reported upper extremity function
measured with QuickDASH questionnaire
Time frame: at 30, 45, 60, 75 and 90 postoperative days
Patient-reported hand function
measured with HQ-8 questionnaire
Time frame: at 30, 45, 60, 75 and 90 postoperative days
Range of motion
Objective thumb range of motion (radial and volar abduction) measured by a blinded assessor
Time frame: at 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.
Strength
Grip strength and pinch strength measured by a blinded assessor
Time frame: at 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.
Migration of prosthesis on cone beam computed tomography
• Long-term radiological assessment with CBCT in the arthroplasty group to assess implant position, migration and loosening and to assess metacarpal 1 migration in the trapeziectomy group
Time frame: at 6 months and 1, 2, 5 and 10 years (with a 1-week reference scan).
Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.
Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 27 months is close to that.
Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahlgrenska University Hospital →